Economic benefit analysis of primary prevention with pravastatin. Modelling economic benefits after such long term treatment is inappropriate.
Pharoah
P
P
D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D003327:Coronary Disease / Q000517:prevention & control*; D003362:Cost-Benefit Analysis; D006801:Humans; D018803:Models, Economic; D017035:Pravastatin / Q000627:therapeutic use*
D000924:Anticholesteremic Agents; D017035:Pravastatin